Aston Martin Lagonda — Institutional Credit Review

As Aston Martin shares and bonds sink to record lows over cash crunch fears (source: FT.com) we use Cognitive Credit AI to run the numbers and produce a detailed Institutional Credit Review highlighting the key operating drivers, risks to investors and investment summary strengths and weaknesses.

Issuer: Aston Martin Lagonda Global Holdings plc

Ticker: ASTONM

Currency: GBP

Accounting Standard: IFRS

Last Reported Period: FY25 (year-end 31 December 2025)

Report Date: April 2026

1. Business Overview

Aston Martin Lagonda (AML) is a British ultra-luxury performance car manufacturer, producing hand-crafted sports cars, grand tourers, and SUVs under the Aston Martin brand. The company operates a single manufacturing site in Gaydon, Warwickshire (UK), with a second facility in St Athan, Wales, used for the DBX SUV. The product portfolio spans core sports cars (Vantage, DB12), the DBX SUV, and a portfolio of high-margin Special and Limited Edition vehicles (Valkyrie, Valhalla). The Valhalla — AML's first series-production plug-in hybrid electric vehicle (PHEV) mid-engined supercar — commenced deliveries in Q4 2025, representing a critical strategic inflection point.

AML sells through an exclusive global dealer network across the Americas, EMEA, and Asia-Pacific. The US and UK are the largest markets; China has declined to approximately 5% of total wholesales as of FY25. The company is deeply capital-intensive, with a product development model that requires continuous investment in new platforms and powertrain technology. Key technology partnerships include Mercedes-AMG (powertrain and electronic architecture) and Lucid Motors (future battery electric vehicle (BEV) platform). AML competes in the ultra-luxury segment alongside Ferrari, Lamborghini, and McLaren, and is differentiated by its British heritage, motorsport association (Formula 1® via Aston Martin Aramco), and bespoke customisation capability.

2. Revenue Model & Operating Drivers

AML's revenue is driven by three interdependent variables: wholesale volume, average selling price (ASP), and product mix (core vs. Specials). In FY25, revenue was £1,257.7m, down 20.6% year-over-year — the sharpest annual decline in the observable history. The revenue decline was driven by a combination of lower Specials deliveries (which carry materially higher ASPs), macroeconomic headwinds, geopolitical uncertainty, and US tariff impacts. Core ASP, however, increased year-over-year, reflecting the benefit of the refreshed core model line-up (DB12, new Vantage).
Structural drivers: AML's revenue model is structurally constrained by its deliberate supply discipline — the company intentionally limits production to protect residual values and brand exclusivity. This creates a ceiling on volume growth but supports pricing power over the cycle. The Specials pipeline (Valhalla, Valkyrie) provides episodic, high-margin revenue that is non-recurring by design.

Cyclical drivers: Demand for ultra-luxury vehicles is highly correlated with global wealth creation, consumer confidence among high-net-worth individuals (HNWIs), and credit availability. The FY25 revenue decline is partly cyclical — EMEA and APAC volumes fell materially — but also reflects structural destocking in certain markets and the timing of new model launches. The US and UK showed relative resilience.

Seasonality: AML's revenue is heavily back-end loaded, with Q4 2025 representing approximately 41% of full-year revenue, driven by planned timing of new core derivatives and initial Valhalla deliveries. This creates significant working capital and cash flow volatility within the year, with a recurring H1 cash burn pattern.

AML's cost structure is predominantly fixed, reflecting the economics of low-volume, hand-crafted manufacturing. In FY25, depreciation and amortisation (D&A) was £339.9m — approximately 27.0% of revenue — the single largest cost item below gross profit and the primary driver of the gap between gross profit and operating profit.

Cost of sales in FY25 was £887.9m, producing a gross margin of 29.4%, down from 36.9% in FY24 and 39.1% in FY23. The gross margin compression reflects lower volumes spreading fixed manufacturing costs over fewer units, adverse product mix (fewer high-margin Specials), and tariff headwinds. Management guided gross margin to recover into the "high 30s%" in FY26, contingent on Valhalla ramp-up and improved core mix.

Operating leverage is highly negative at current volumes. Because fixed costs dominate, each unit of volume lost has an outsized impact on EBITDA. The FY25 Company Reported Adjusted EBITDA fell 60.1% year-over-year to £108.1m on a revenue decline of only 20.6%, illustrating the severe operating leverage effect. Adjusted EBITDA margin compressed from 17.1% in FY24 to 8.6% in FY25.

Key cost inputs include aluminium, carbon fibre (Specials), powertrain components (sourced from Mercedes-AMG), and skilled labour. The company has limited ability to flex costs in the short term given the bespoke nature of production.

4. Unit Economics & Cash Generation

Adj. EBITDA = Company Reported Adjusted EBITDA (Management Adjusted EBITDA). Margins from the Metrics sheet. FCF from the Cash Flow Statement.

Cash conversion is structurally poor. AML has generated negative free cash flow in every year of observable history. In FY25, FCF was negative £424.7m, driven by CFO of £74.1m, net interest paid of £147.8m, lease payments of £10.0m and capital expenditure of £341.0m. The investing outflow is dominated by capitalised technology and development expenditure — a structural feature of the business model rather than a cyclical anomaly.

Working capital is a source of intra-year volatility. The back-end loaded delivery profile means AML builds inventory and incurs costs in H1, with cash collection concentrated in H2/Q4. This creates a recurring H1 cash burn pattern that requires adequate liquidity headroom.

Capex intensity is very high. Total investing outflows were £227.7m in FY25 (down from £374.8m in FY24), representing approximately 18.1% of revenue. Management has revised the 5-year capex plan down from approximately £2.0bn to £1.7bn, primarily by deferring EV platform investment. Maintenance vs. growth capex split is not explicitly disclosed in available documents. 

5. Liquidity Position

Cash on hand: £249.9m at 31 December 2025 (FY24: £359.6m).

Revolving Credit Facility (RCF) — The £170.0m RCF was effectively fully drawn at 31 December 2025:

• Cash drawn: £164.0m
• Financial guarantees/letters of credit: £5.4m
• Total utilised: £169.4m
• Remaining undrawn headroom: £0.6m
• Maturity: 31 December 2028 (Source: ASTONM_FY25.pdf, pp. 177, 206)

HSBC Bilateral RCF: £50.0m facility, undrawn at 31 December 2025. Reduces to £25.0m on 21 March 2027, available until at least 21 March 2028. The HSBC Bilateral facility requires Chinese Renmibi to be deposited into a restricted account with HSBC in China in exchange for a Sterling overdraft facility in the United Kingdom. (Source: ASTONM_FY25.pdf, pp. 206, 211)

Total available liquidity at year-end:

This compares to the £565.8m available at 31 December 2024 (which included the then largely undrawn primary RCF). The year-over-year reduction of approximately £265.3m reflects the £424.7m FCF burn, partially offset by £106m net proceeds from AMR GP share sales and £52.5m from the Yew Tree equity investment. Management's own disclosure references "£250m in total cash and available facilities" as of 31 December 2025, consistent with the figure above. (Source: ASTONM_FY25.pdf, p. 165)

Committed inflow: £50m from the sale of naming rights to AMR GP Holdings Limited, expected in Q1 2026, which would bring total liquidity to approximately £350m. (Source: ASTONM_FY25.pdf, p. 165)

Near-term maturity schedule: The Senior Secured Notes (SSNs) — £565.0m at 10.375% and $1,050.0m at 10.0% — both mature in March 2029. The primary RCF matures December 2028. The HSBC bilateral RCF reduces to £25.0m in March 2027 and matures March 2028. There are no material debt principal maturities in the next 24 months, but the RCF maturity in December 2028 is only 8 months ahead of the SSN maturity, creating a compressed refinancing window. (Source: ASTONM_FY25.pdf, p. 206)

Covenant structure: The RCF leverage covenant is tested quarterly from March 2027 (not currently tested), triggered only when drawn amount less unrestricted cash exceeds 40% of facility. The covenant metric is adjusted EBITDA to net debt (with lease liabilities calculated under frozen GAAP / IAS 17). Management proactively amended the RCF terms with lending banks to push the first test to March 2027. Management expects compliance through the going concern review period (to 30 June 2027). (Source: ASTONM_FY25.pdf, pp. 157, 177)

Reverse stress test: Management disclosed that total core vehicle volumes would need to fall more than 10% from forecast to exhaust liquidity, and 4% to breach covenants. Given FY25 volumes already fell 10% year-over-year, these thresholds are uncomfortably thin. (Source: ASTONM_FY25.pdf, p. 178)

12–24 month liquidity runway assessment: With approximately £300m of available liquidity (cash + undrawn HSBC facility) and an annualised FCF burn of approximately £424.7m, the pure cash burn runway is approximately 8–9 months before mitigating actions — a critically thin margin. The £50m F1 naming rights proceeds (Q1 2026) extend this to approximately 9–10 months. The ability to constrain discretionary capex is the most meaningful lever: management has demonstrated historical control over capex vs. forecasts, and a reduction of £100m–£150m in annual capex would extend the runway materially. However, any such reduction would delay product development and risk competitive positioning.

The absence of near-term debt principal maturities (SSNs due March 2029) removes immediate refinancing pressure, but the RCF covenant test in March 2027 is a key near-term credit event. The going concern assessment was approved without material uncertainty, but the margin of safety is narrow and dependent on operational execution. The HSBC bilateral RCF reducing to £25.0m in March 2027 — precisely when the leverage covenant test begins — further tightens the liquidity buffer at the most critical juncture. 

6. Capital Structure & Funding Model

Debt stack (as at 31 December 2025):

SSN carrying value (net of unamortised costs/discounts): £1,329.8m. The bank loans/overdrafts line of £170.4m in the debt note is consistent with the drawn RCF of £164.0m plus other facilities.

Interest cost: Net cash interest was £143.0m in FY25. Effective interest rate was approximately 9.1% on gross debt. The SSNs are fixed-rate instruments (10.375% and 10.0%), providing certainty on the largest portion of interest cost. The RCF is floating rate (specific terms not retrieved).

Leverage: Adjusted Net Leverage (Management definition) was 12.8x at FY25 year-end, up from 4.3x at FY24 year-end, driven by the collapse in Adjusted EBITDA. Derived EBITDA-based Net Leverage was 17.1x — a figure that reflects the severity of the EBITDA deterioration in FY25.

Interest coverage: The Adjusted EBITDA interest coverage ratio was 0.76x in FY25 — below 1.0x, meaning Adjusted EBITDA does not cover cash interest expense. This is a critical credit signal: the company is not generating sufficient operating cash flow to service its debt from operations alone.

Capital intensity: AML is one of the most capital-intensive businesses in the high yield universe relative to its revenue base. Investing outflows of £227.7m on revenue of £1,257.7m represent approximately 18.1% of revenue, funded entirely by debt and equity issuance given persistent negative FCF.

Historical refinancing behaviour: AML refinanced all existing SSNs in March 2024, issued additional notes in August 2024 and November 2024, and proactively amended RCF covenants in FY25. The company has demonstrated a pattern of accessing capital markets ahead of stress, but at progressively higher coupons (10%+ on the 2024 SSNs). Transaction costs on 2024 issuances were £24.0m. (Source: ASTONM_FY25.pdf, p. 212)

Equity base: Total shareholders' equity was £329.2m at FY25 year-end, down from £752.9m at FY24, driven by the £493.0m net loss. Retained earnings deficit stands at £(2,182.7)m, reflecting cumulative losses since IPO. The equity base is being eroded rapidly.

Leases: IFRS 16 lease liabilities of £91.8m are included in gross debt. The company uses frozen GAAP (IAS 17) for covenant calculations, which excludes lease liabilities from the covenant net debt definition — a favourable adjustment for covenant compliance. 

7. Balance Sheet Quality

Asset quality is dominated by intangibles. Intangible assets were £1,644.8m at FY25 year-end (58.6% of total assets of £2,805.5m), comprising primarily capitalised development costs (net book value £934.3m), goodwill on brands (£297.6m), goodwill on technology (£85.4m), acquired MBAG technology (£130.0m), and Lucid technology (£188.5m — not yet amortising). PP&E was £351.5m. The tangible asset base is therefore modest relative to the debt load — total gross debt of £1,631.6m significantly exceeds tangible assets (PP&E + inventory + receivables + cash ≈ £1,081m), implying limited tangible asset coverage for creditors.

Deferred tax asset (DTA): AML wrote down its net DTA by £126.4m in FY25 to nil, reflecting increased uncertainty about the timing of future taxable profits.

Pension: Inclusive of an adjustment to reflect minimum funding, the defined benefit pension scheme had a deficit of £34.2mn at FY25 year-end vs 28.7mn deficit in FY24. (Source: ASTONM_FY25.pdf, pp. 217–219.

Inventory: £277.7m at FY25 year-end. Given the bespoke, low-volume nature of production, inventory is relatively illiquid and would realise significant discounts in a distressed scenario.

Impairment: A £42.7m impairment of capitalised development spend was recorded in FY25 following the strategic review of the product cycle plan and discontinuation of certain vehicle programmes. (Source: ASTONM_FY25.pdf, p. 195)

Contingent liabilities: Specific details not retrieved from available documents. 

8. Accounting Quality & Red Flags

Capitalised development costs are the most significant accounting judgement. AML capitalises substantially all product development expenditure under IAS 38, with £226.5m of additions in FY25 (gross cost additions). The net book value of capitalised development costs is £934.3m. This treatment is IFRS-compliant and audited, but it means that the income statement does not reflect the true cash cost of product development — instead, amortisation (£171.9m in FY25 on development costs alone) is spread over 1–10 years. This creates a structural gap between reported EBITDA and cash generation.

Deferred tax asset write-down (£126.4m): Recorded through the income statement as a tax charge, this inflated the reported net loss to £493.0m in FY25 and is a clear signal that management no longer believes near-term profitability is sufficient to utilise tax losses. (Source: ASTONM_FY25.pdf, p. 116)

Lucid technology (£188.5m): This acquired technology asset has not yet commenced amortisation as it is not yet available for use. When amortisation begins, it will add a further charge to the income statement, further pressuring reported earnings. (Source: ASTONM_FY25.pdf, p. 192)

Revenue recognition: AML recognises revenue on wholesale (delivery to dealer) rather than retail (delivery to end customer). In periods of destocking, this can create a disconnect between reported revenue and underlying consumer demand. 

9. Corporate Governance & Financial Policy

Ownership: AML has a concentrated, multi-party ownership structure. Lawrence Stroll (via Yew Tree Consortium) holds 32.99% of voting rights and serves as Executive Chairman. Other major shareholders include Ernesto Bertarelli (14.92%), Geely/Li Shufu (14.08%), Saudi Arabia's Public Investment Fund (PIF) (13.88%), and Mercedes-Benz AG (7.54%). (Source: ASTONM_FY25.pdf, p. 95)

Board composition: The board comprises 15 directors: Executive Chairman (Lawrence Stroll), CEO (Adrian Hallmark), CFO (Doug Lafferty), and 12 non-executive directors of which 6 are independent. (Source: ASTONM_FY25.pdf, p. 95)

Executive compensation: CEO Adrian Hallmark (appointed 1 September 2024) received total remuneration of £1,617,000 in FY25, including salary of £1,000,000 and annual bonus of £350,000. CFO Doug Lafferty received total remuneration of £1,016,000. The LTIP framework links vesting to performance conditions including revenue, earnings, share price, ESG delivery, and shareholder experience. Neither the CEO (12.7% of salary held) nor the CFO (38.6% of salary held) has met their shareholding guidelines (300% and 200% of salary respectively), reflecting recent tenure and the depressed share price. (Source: ASTONM_FY25.pdf, pp. 137, 144)

Financial policy: AML has no stated leverage target or dividend policy. Capital allocation is entirely directed toward product development and debt service. The company has relied on equity issuances and debt refinancings to fund operations, with no path to positive FCF disclosed in the near term. The proactive RCF amendment and capex reduction signal a pragmatic, liquidity-focused financial policy under the current CEO.

Credit-relevant governance signal: The concentrated ownership (Stroll at 33%) provides strategic stability and demonstrated willingness to inject capital (multiple equity raises since 2020), but also creates potential for decisions that prioritise brand/strategic objectives over near-term creditor interests. 

10. Peer Comparison

The following table presents LTM comparables for AML and selected peers in the Automobile Manufacturers sub-industry. Note that BMW, Mercedes-Benz, and Volkswagen are mass-market/premium OEMs included for context only; Ferrari is the most directly comparable ultra-luxury peers. All figures are in each company's reporting currency (not converted). All companies report under IFRS. 

Relative positioning:

• Revenue growth: AML's (20.6%) revenue decline is the worst in the peer set, contrasting sharply with Ferrari's +7.0% growth. This reflects AML's acute volume and mix headwinds in FY25 and underscores the structural gap between AML and Ferrari in terms of demand resilience.

• EBITDA margin: AML's Adjusted EBITDA margin of 8.6% is dramatically below Ferrari's 38.8%. AML's margin is structurally constrained by its high fixed cost base and D&A burden. 

• FCF: AML's FCF/Net Debt of (30.7%) is deeply negative, versus Ferrari's strongly positive 97.6% and Volkswagen's 14.8%. AML is a persistent cash consumer; Ferrari is a cash generator. This is the most fundamental credit differentiator.

Leverage: AML's Adjusted Net Leverage of 12.8x is extreme relative to Ferrari's 0.51x and Volkswagen's 1.35x. Even adjusting for the cyclical EBITDA trough, AML's leverage is structurally elevated and incompatible with investment-grade metrics. The company is firmly in distressed high yield territory. 

11. Legal Structure, Jurisdiction & Documentation

AML is domiciled in England and Wales, with the listed holding company being Aston Martin Lagonda Global Holdings plc. The operating subsidiaries (including Aston Martin Lagonda Limited, the primary trading entity) sit below the holding company. The SSNs are issued at the operating subsidiary level and are secured against the assets of the group, providing senior secured creditors with direct recourse to the manufacturing assets, intellectual property, and brand. The RCF ranks pari passu with the SSNs.

Recovery implications: Senior secured creditors benefit from first-ranking security over the asset base. However, the tangible asset coverage is limited — PP&E of £351.5m and inventory of £277.7m provide approximately £629m of tangible collateral against £1,631.6m of gross debt, implying a tangible coverage ratio of approximately 39%. The intangible asset base (£1,644.8m) is the largest component of the balance sheet but would realise significant discounts in a distressed sale, given the brand-specific and development-stage nature of many assets. The Aston Martin brand itself has significant franchise value, but this is difficult to monetise independently of the operating business.

Structural subordination risk is limited given the SSNs are issued at the operating level. However, the holding company structure means that equity holders and any holding company creditors would rank behind the SSN holders in a recovery scenario.

12. Valuation (Credit-Relevant)

Enterprise value support: At the FY25 Company Reported Adjusted EBITDA of £108.1m, applying a 6–8x EV/EBITDA multiple (consistent with distressed ultra-luxury automotive peers) implies an enterprise value (EV) of approximately £648m–£865m. Against total gross debt of £1,631.6m, this implies a significant shortfall for creditors on a going-concern basis at current EBITDA levels. At a normalised Adjusted EBITDA of approximately £300m (consistent with FY23 levels), a 6–8x multiple implies EV of £1,800m–£2,400m, which would provide full coverage of the SSNs at the lower end of the range.

Liquidation framework: In a distressed scenario, the most recoverable assets would be: (i) the Aston Martin brand and intellectual property (franchise value — difficult to quantify but potentially £500m–£1bn+ in a strategic sale to a luxury conglomerate); (ii) PP&E (£351.5m book, likely 40–60% recovery = £140m–£210m); (iii) inventory (£277.7m book, likely 30–50% recovery = £83m–£139m); (iv) cash (£249.9m at face value). Total estimated liquidation recovery: approximately £1,000m–£1,600m, suggesting partial-to-full recovery for senior secured creditors depending on brand valuation assumptions. Unsecured creditors would face significant losses.

Key credit protection: The brand franchise value is the primary credit support. AML's 111-year heritage, Formula 1 association, and ultra-luxury positioning create a floor on enterprise value that is not reflected in the current EBITDA-based multiples. A strategic acquirer (luxury conglomerate, sovereign wealth fund) would likely ascribe significant value to the brand above and beyond the operating business. 

13. Downside Case Analysis

Macro/industry trigger: A global recession or sharp decline in HNWI wealth (e.g., equity market correction of 30%+), combined with sustained US tariff escalation on UK-manufactured vehicles, would be the most damaging scenario. AML's US exposure is significant (largest single market), and a 25% tariff on UK car imports would either compress margins (if absorbed) or reduce demand (if passed through).

Revenue/margin impact: A 15–20% further volume decline from FY25 levels combined with ASP pressure would reduce revenue to approximately £1,000m–£1,050m. At a gross margin of 25–27%, gross profit would fall to approximately £250m–£280m. With fixed operating costs largely unchanged, Adjusted EBITDA could approach zero or turn negative.

Liquidity burn: With the primary RCF now effectively fully drawn (£164.0m drawn, £0.6m headroom), the liquidity buffer is materially thinner than previously assessed. At zero EBITDA, cash interest of approximately £143m and capex of approximately £300-400m (minimum maintenance level) would imply a cash burn of over £400m per annum. With approximately £300m of available liquidity (cash + undrawn HSBC facility), the runway would be approximately 10–11 months before exhaustion — before the Q1 2026 £50m F1 naming rights proceeds. This is a critically short runway that leaves almost no margin for operational setbacks.

Covenant pressure: The RCF leverage covenant test begins in March 2027. Under the downside scenario, if Adjusted EBITDA is near zero, the covenant would be breached immediately upon testing. Management's reverse stress test indicated a 4% volume shortfall from forecast would breach covenants — a thin margin given the macro uncertainty. Critically, the RCF is already drawn to £164.0m, meaning the covenant trigger condition (drawn amount less unrestricted cash exceeding 40% of facility = £68m) is already met at current draw levels. This means the covenant is effectively live from March 2027 regardless of whether additional drawings are made.

Refinancing risk: The SSNs mature in March 2029. In a downside scenario with near-zero EBITDA and negative FCF, refinancing £1.3bn+ of SSNs in 2028 would be extremely challenging. The 10%+ coupon on the existing SSNs already reflects significant credit risk; a distressed refinancing could require materially higher coupons or structural concessions. The compressed refinancing window — RCF matures December 2028, SSNs mature March 2029 — means both instruments would need to be addressed simultaneously, increasing execution risk.

How default could occur: Default would most likely be triggered by: (i) RCF covenant breach in March 2027 if EBITDA does not recover; (ii) liquidity exhaustion within 10–12 months if cash burn accelerates and no equity injection is forthcoming; or (iii) inability to refinance the SSNs ahead of March 2029 maturity.

Where losses crystallise: Senior secured SSN holders would face losses if the enterprise value at default is below £1,631.6m. Given the brand franchise value, full loss is unlikely, but partial impairment (20–40% haircut) is plausible in a distressed scenario. Equity holders would be wiped out.

Recovery path: The most likely recovery mechanism is a strategic sale of the business (brand + IP + manufacturing) to a luxury conglomerate or sovereign-backed entity. A debt-for-equity swap is also possible, converting SSN holders into equity owners of a deleveraged entity.

14. Key Risks (Ranked by Credit Materiality)

• Liquidity exhaustion risk (near-term, 0–12 months): With the primary RCF fully drawn and only approximately £300m of available liquidity against approximately £410m annualised FCF burn, the runway is approximately 10–11 months on a pure burn basis before the Q1 2026 £50m F1 naming rights proceeds. This is the most immediate credit risk. Any operational setback — production disruption, demand shock, tariff escalation — could exhaust liquidity before the March 2027 covenant test. Probability: Medium-High; Severity: Existential.
• Refinancing risk (March 2029 SSN maturity): AML must refinance approximately £1.3bn of SSNs by March 2029 while generating negative FCF and carrying 12.8x adjusted leverage. Market access will depend critically on EBITDA recovery in 2026–2028. The compressed refinancing window (RCF and SSNs both mature within 3 months of each other) amplifies execution risk. Probability: High; Severity: Existential.
• EBITDA recovery failure: FY25 Adjusted EBITDA of £108.1m is 60% below FY24 and 65% below FY23. Recovery depends on Valhalla ramp-up, new core model derivatives, and gross margin expansion. If volumes disappoint or ASP erodes further, EBITDA could remain depressed, making both liquidity management and refinancing impossible. Probability: Medium-High; Severity: Very High.
• US tariff escalation: AML manufactures exclusively in the UK and exports a significant proportion of volumes to the US. A sustained 25% tariff on UK-manufactured vehicles would either compress margins materially or reduce demand. Management has not disclosed a specific tariff mitigation plan. Probability: Medium; Severity: High.
• RCF covenant breach (March 2027): The leverage covenant test begins in March 2027. With the RCF already drawn to £164.0m, the covenant trigger condition is effectively met at current draw levels. A 4% volume shortfall from forecast would breach the covenant per management's own reverse stress test. Probability: Medium; Severity: High.

Most important upside leading indicators:

• Quarterly Adjusted EBITDA trending toward £50m+ per quarter (implying annualised run-rate of £200m+)
• Valhalla delivery volumes tracking toward 500 units in FY26
• Gross margin recovering toward the "high 30s%" as guided
• Successful equity raise or strategic investment providing liquidity buffer

Most important downside leading indicators:

• Cash balance falling below £150m (approaching minimum operating liquidity)
• Quarterly wholesale volumes falling below 1,200–1,300 units

15. Investment View Summary

Credit strengths:

• Iconic, 111-year-old brand with genuine franchise value providing a floor on enterprise value in a distressed scenario
• No near-term debt principal maturities (SSNs due March 2029, primary RCF due December 2028)
• HSBC bilateral RCF of £50.0m remains undrawn, providing a modest liquidity buffer, but requires Renminbi deposit
• Covenant test deferred to March 2027, providing operational runway
• Concentrated, committed shareholder base (Stroll, PIF, Geely, Mercedes-Benz) with demonstrated willingness to inject capital
• Valhalla launch provides a credible near-term EBITDA recovery catalyst

Credit weaknesses:

• Primary RCF effectively fully drawn (£164.0m of £170.0m) — available liquidity is approximately £300m
• Persistently negative FCF (£425m outflow in FY25) with no near-term path to positive cash generation
• Liquidity runway of approximately 10–11 months on a pure burn basis — critically thin
• Extreme leverage (Adjusted Net Leverage 12.8x) with EBITDA at a multi-year trough
• High fixed cost base and severe operating leverage — small volume declines cause disproportionate EBITDA compression
• Intangible-heavy balance sheet with limited tangible asset coverage for creditors
• DTA write-down signals management's own lack of confidence in near-term profitability
• Refinancing of £1.3bn+ SSNs in 2028 is a high-stakes event with significant execution risk
• Exposure to US tariffs, China demand weakness, and macro cyclicality

What would cause deterioration:

• Valhalla delivery shortfall or quality issues
• Further volume/ASP decline driven by tariffs or macro weakness
• Inability to access equity markets for additional capital
• Cash balance declining below £150m, triggering going concern concerns
• Covenant breach in March 2027 triggering RCF acceleration

What would improve the credit:

• Sustained EBITDA recovery toward £250m–£300m+ (FY23 levels) by FY27
• Equity injection of £200m+ from existing or new shareholders, restoring liquidity headroom
• Successful early refinancing of SSNs (2027) at manageable coupons
• Positive FCF generation (even modestly) demonstrating cash flow inflection

Bottom-line assessment: STRESSED/DISTRESSED PROFILE. Aston Martin is a high-conviction brand with genuine franchise value, but the credit profile is deeply stressed. The combination of extreme leverage, persistent negative FCF, a near-term EBITDA trough, and a £1.3bn refinancing wall in March 2029 creates a binary outcome: either EBITDA recovers materially in 2026–2027 (enabling refinancing), or the company faces a restructuring. The brand's strategic value provides a meaningful recovery floor for senior secured creditors, but the path to par is narrow and highly execution-dependent. This is a credit that requires active monitoring of quarterly volume and EBITDA trends as leading indicators of refinancing feasibility. 

Credit Score Appendix

This analysis was generated by Cognitive Credit AI and verified by Cognitive Credit analysts. 

Want to try Cognitive Credit AI? Request a demo today.

Disclaimer: This analysis is based on sector-level reasoning and is intended for informational purposes only. It does not constitute investment advice. Specific issuer-level impacts will vary based on individual hedging programmes, contract structures, geographic exposure, and liquidity positions. Cognitive Credit's company-level financial data should be used for issuer-specific analysis.